Risankizumab-800CW
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Risankizumab-800CW, covering 2025-03-05 to 2026-01-14. Get the full timeline:
Most recent: Clinical Trial Update: Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease [Phase 1, Phase 2]